yingweiwo

PHA-665752

Alias: PHA-665752; PHA665752; PHA-665752 hydrate; TCMDC-125885; UNII-0VXU5T5R3J; (R,Z)-5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA 665752
Cat No.:V0591 Purity: ≥98%
PHA-665752 (PHA665752) is a novel, potent, selective and ATP-competitive small molecule inhibitor of c-Met Kinase with potential antitumor activity.
PHA-665752
PHA-665752 Chemical Structure CAS No.: 477575-56-7
Product category: c-MET
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

PHA-665752 (PHA665752) is a novel, potent, selective and ATP-competitive small molecule inhibitor of c-Met Kinase with potential antitumor activity. In cell-free experiments, it inhibits c-Met with an IC50 of 9 nM and demonstrates >50-fold selectivity in inhibiting c-Met relative to other kinases like RTKs or STKs. It has the ability to target human cancers with overactivated c-Met. By inhibiting the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells, it demonstrates strong anti-proliferative activity in vitro.

Biological Activity I Assay Protocols (From Reference)
Targets
c-Met (IC50 = 9 nM); RON (IC50 = 68 nM); Flk1 (IC50 = 200 nM)
ln Vitro
The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the development and progression of several human cancers and are attractive targets for cancer therapy. PHA-665752 was identified as a small molecule, ATP-competitive, active-site inhibitor of the catalytic activity of c-Met kinase (K(i) 4 nM). PHA-665752 also exhibited >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. In cellular studies, PHA-665752 potently inhibited HGF-stimulated and constitutive c-Met phosphorylation, as well as HGF and c-Met-driven phenotypes such as cell growth (proliferation and survival), cell motility, invasion, and/or morphology of a variety of tumor cells. In addition, PHA-665752 inhibited HGF-stimulated or constitutive phosphorylation of mediators of downstream signal transduction of c-Met, including Gab-1, extracellular regulated kinase, Akt, signal transducer and activator of transcription 3, phospholipase C gamma, and focal adhesion kinase, in multiple tumor cell lines in a pattern correlating to the phenotypic response of a given tumor cell.[1]
PHA665752 specifically inhibited cell growth in BaF3. TPR-MET cells (IC(50) < 0.06 micromol/L), induced apoptosis and cell cycle arrest. Constitutive cell motility and migration of the BaF3. TPR-MET cells was also inhibited. PHA665752 inhibited specific phosphorylation of TPR-MET as well as phosphorylation of downstream targets of the mammalian target of rapamycin pathway. When combined with PHA665752, rapamycin showed cooperative inhibition to reduce growth of BaF3. TPR-MET- and c-MET-expressing H441 NSCLC cells. Conclusions: PHA665752 is a potent small molecule-selective c-MET inhibitor and is highly active against TPR-MET-transformed cells both biologically and biochemically. PHA665752 is also active against H441 NSCLC cells. The c-MET inhibitor can cooperate with rapamycin in therapeutic inhibition of NSCLC, and in vivo studies of this combination against c-MET expressing cancers would be merited.[2]

PHA-665752 shows >50-fold selectivity for c-Met in comparison to different tyrosine and serine-threonine kinases, and it significantly inhibits c-Met kinase activity with a Ki of 4 nM. HGF-stimulated c-Met autophosphorylation is potently inhibited by PHA-665752, with an IC50 of 25–50 nM. Additionally, PHA-665752, with an IC50 of 18–42 nM and 40–50 nM, respectively, strongly inhibits HGF- and c-Met-dependent processes like cell motility and proliferation. Furthermore, PHA-665752 significantly suppresses constitutive or HGF-stimulated phosphorylation of downstream c-Met mediators, including Gab-1, ERK, Akt, STAT3, PLC-γ, and FAK, in a variety of tumor cell lines.[1] PHA-665752 suppresses constitutive cell motility and migration by 92.5% at 0.2 μM and inhibits cell growth in TPR-MET-transformed BaF3 cells with an IC50 of less than 60 nM. When PHA665752 (0.2 μM) inhibits c-Met, it also causes 33.1% of cells to undergo apoptosis and G1 cell cycle arrest, increasing the percentage of cells in the G1 phase from 42.4% to 77.0%. PHA665752 and rapamycin can work together to stop the growth of BaF3 cells that have been transformed by TPR-MET and H441 cells that are not small cell lung cancer.[2]

ln Vivo
The c-Met receptor tyrosine kinase is emerging as a novel target in many solid tumors, including lung cancer. PHA-665752 was identified as a small molecule, ATP competitive inhibitor of the catalytic activity of the c-Met kinase. Here, we show that treatment with PHA665752 reduced NCI-H69 (small cell lung cancer) and NCI-H441 (non-small cell lung cancer) tumorigenicity in mouse xenografts by 99% and 75%, respectively. Reduction in tumor size was also observed by magnetic resonance imaging of tumors in mice. PHA665752 inhibited c-Met phosphorylation at the autophosphorylation and c-Cbl binding sites in mouse xenografts derived from non-small cell lung cancer cell lines (NCI-H441 and A549) and small cell lung cancer cell line (NCI-H69). PHA665752 also inhibited angiogenesis by >85% in all the abovementioned cell lines and caused an angiogenic switch which resulted in a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These studies show the feasibility of selectively targeting c-Met with ATP competitive small molecule inhibitors and suggest that PHA665752 may provide a novel therapeutic approach to lung cancer.[3]
In in vivo studies, a single dose of PHA-665752 inhibited c-Met phosphorylation in tumor xenografts for up to 12 h. Inhibition of c-Met phosphorylation was associated with dose-dependent tumor growth inhibition/growth delay over a repeated administration schedule at well-tolerated doses. Interestingly, potent cytoreductive activity was demonstrated in a gastric carcinoma xenograft model. Collectively, these results demonstrate the feasibility of selectively targeting c-Met with ATP-competitive small-molecules and suggest the therapeutic potential of targeting c-Met in human cancers[1].
S114 xenografts are dose-dependently inhibited in terms of tumor growth by PHA-665752, with doses of 7.5, 15, and 30 mg/kg/day causing increases of 20%, 39%, and 68%, respectively.[1] NCI-H69, NCI-H441, and A549 tumor growth in mouse xenografts is dramatically reduced by PHA665752 treatment by 99%, 75%, and 59%, respectively. Moreover, PHA665752 dramatically reduces angiogenesis by more than 85% by raising the angiogenesis inhibitor thrombospondin-1 and lowering the vascular endothelial growth factor producing process.[3]
Enzyme Assay
The c-Met assay uses the GST-fusion protein containing the c-Met kinase domain. Based on the phosphorylation of kinase peptide substrates or poly-glu-tyr in the presence of ATP and divalent cations (MgCl2 or MnCl2 10–20 mM), PHA-665752's IC50 value for the inhibition of c-Met is determined. For c-Met, the linear range—that is, the duration during which the rate stays equal to the initial rate—is established, and the kinetic measurement and IC50 calculation are carried out inside of this range.
Cell Assay
Cells are grown in 0.1% FBS medium for 48 hours in order to perform proliferation assays. Afterward, the cells are treated with varying concentrations of PHA-665752 in HGF (50 ng/mL) in a medium containing 2% FBS. Following 18 hours, cells are fixed, stained with an anti-BrdUrd peroxidase-conjugated antibody, and then incubated with BrdUrd for an hour. The plates are then read at 630 nm. Cells are grown in 2% FBS medium with and without HGF (50 ng/mL) and different concentrations of PHA-665752 for 72 hours in order to perform apoptosis assays. After 72 hours, a mixture containing acridine orange and ethidium bromide is added, and fluorescent microscopy is used to count the number of apoptotic cells (bright orange cells or cell fragments).
The effect of PHA665752 treatment was determined on cell growth, motility and migration, apoptosis, and cell-cycle arrest of TPR-MET-transformed cells. Moreover, the effect of PHA665752 on the phosphorylation on MET, as well as its downstream effectors, p-AKT and p-S6K, was also determined. Finally, growth of TPR-MET-transformed cells was tested in the presence of PHA665752 and rapamycin. H441 non-small cell lung cancer (NSCLC) cells (with activated c-Met) were also tested against both PHA665752 and rapamycin [2].
Animal Protocol
Female athymic mice (nu/nu) bearing S114 or GTL-16 tumor xenografts
~30 mg/kg/day
Injection via bolus i.v.
Treatment of Nude Mice for Studying the Effect of c-Met Tyrosine Kinase Inhibitors on Tumorigenicity and Immunohistochemistry of Tumors[3]
NCI-H441, A549, and NCI-H69 cells were cultured and harvested with trypsin/EDTA. The viability of these cells was determined by trypan blue and only cell populations with 90% or greater viability were used for this investigation. The tumorigenicity of these lung cancer cells was determined by intradermally injecting 5 × 106 viable cells in balanced salt solution into the flank or leg region of nude mice to produce s.c. tumors. Once daily intratumoral injections of PHA665752, were given 8 days after the lung cancer cells were injected when tumors were visible. One group of animals was given PHA665752 (16.5 μg in 100 μL of 2% DMSO) and group 2 was injected with diluent (2% DMSO) alone. The mice were euthanized at the indicated times and tumors were measured with calipers, fixed in 4% formalin, embedded in paraffin, and stained with H&E.[3]
Immunohistochemical staining of tumors was done using monoclonal antibodies against CD31, VEGF, TSP-1, and phosphospecific antibodies to c-Met pY1230/1234/1235 and pY1003. The immunostaining procedures used have been previously described by Ma et al. Appropriate negative controls for the immunostaining were prepared by omitting the primary antibody step and substituting it with nonimmune rabbit serum. To estimate the number of blood vessels in tumors before and after treatment, 10 microscopic fields were counted at 20× magnification and the number of blood vessels were evaluated. All of the slides were reviewed and scored by two investigators independently.[3]
References

[1]. Cancer Res . 2003 Nov 1;63(21):7345-55.

[2]. Clin Cancer Res . 2005 Mar 15;11(6):2312-9.

[3]. Cancer Res . 2007 Apr 15;67(8):3529-34.

Additional Infomation
PHA-665752 is a member of the class of indolones that is 1,3-dihydro-2H-indol-2-one which is substituted by a (2,6-dichlorobenzyl)sulfonyl group at position 5 and by a (1H-pyrrol-2-yl)methylidene group at position 2, the pyrrole ring of which is substituted by methyl groups at positions 3 and 5, and by a [2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl group at position 4 (the Z,R isomer). It has a role as a c-Met tyrosine kinase inhibitor and an antineoplastic agent. It is a member of indolones, a pyrrolecarboxamide, a N-acylpyrrolidine, a sulfone, a dichlorobenzene, an enamide, a secondary carboxamide and a tertiary carboxamide.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C32H34CL2N4O4S
Molecular Weight
641.61
Exact Mass
640.167
Elemental Analysis
C, 59.90; H, 5.34; Cl, 11.05; N, 8.73; O, 9.97; S, 5.00
CAS #
477575-56-7
Related CAS #
477575-56-7
PubChem CID
10461815
Appearance
Yellow to orange solid powder
Density
1.4±0.1 g/cm3
Boiling Point
890.2±65.0 °C at 760 mmHg
Flash Point
492.2±34.3 °C
Vapour Pressure
0.0±0.3 mmHg at 25°C
Index of Refraction
1.656
LogP
4
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
7
Heavy Atom Count
43
Complexity
1180
Defined Atom Stereocenter Count
1
SMILES
ClC1C([H])=C([H])C([H])=C(C=1C([H])([H])S(C1C([H])=C([H])C2=C(C=1[H])/C(/C(N2[H])=O)=C(\[H])/C1=C(C([H])([H])[H])C(=C(C([H])([H])[H])N1[H])C(N1C([H])([H])C([H])([H])C([H])([H])[C@]1([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H])=O)(=O)=O)Cl
InChi Key
OYONTEXKYJZFHA-SSHUPFPWSA-N
InChi Code
InChI=1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1
Chemical Name
(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one
Synonyms
PHA-665752; PHA665752; PHA-665752 hydrate; TCMDC-125885; UNII-0VXU5T5R3J; (R,Z)-5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA 665752
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~128 mg/mL (~199.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: 2.5 mg/mL (3.90 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (3.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly..


Solubility in Formulation 4: 2% DMSO+castor oil: 5 mg/mL

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.5586 mL 7.7929 mL 15.5858 mL
5 mM 0.3117 mL 1.5586 mL 3.1172 mL
10 mM 0.1559 mL 0.7793 mL 1.5586 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • PHA-665752

  • PHA-665752
  • PHA-665752
Contact Us